Capital Planning Advisors LLC Increases Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Capital Planning Advisors LLC boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 41.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 106,565 shares of the biotechnology company’s stock after buying an additional 31,003 shares during the quarter. Capital Planning Advisors LLC’s holdings in Heron Therapeutics were worth $163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cutter & CO Brokerage Inc. acquired a new stake in Heron Therapeutics in the third quarter valued at about $39,000. Y Intercept Hong Kong Ltd purchased a new position in Heron Therapeutics in the third quarter valued at about $39,000. B. Riley Wealth Advisors Inc. purchased a new position in Heron Therapeutics in the second quarter valued at about $41,000. Sei Investments Co. purchased a new position in Heron Therapeutics in the second quarter valued at about $44,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Heron Therapeutics during the 3rd quarter worth approximately $45,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on HRTX shares. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Wednesday, December 4th.

Heron Therapeutics Stock Up 3.6 %

Shares of HRTX opened at $1.69 on Thursday. The firm has a market cap of $256.90 million, a PE ratio of -9.38 and a beta of 1.60. The company’s fifty day moving average is $1.48 and its two-hundred day moving average is $1.92. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same quarter last year, the business earned ($0.17) EPS. As a group, equities research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.